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Diagnosing prostate cancer seemed to be “simple” 30 
or 40 years ago, since we diagnosed it by rectal digital 
examination (RDE). After this, we carried out castration 
and the patient was administered a terrible amount of 
estrogen hormone (cca 20-25 mg). As a consequence, he 
died either due to the tumorous disease or the side effects 
of our treatment. In the case of false positive RDE, the 
treatment turned out to be false as well…
The beginning
The discovery of PSA was an extremely important event 
in our clinical practice; however we were not aware of 
its importance at that time. I was working in West Ger-
many in the middle of 1980s when the measurement 
of PSA was clinically introduced – still surrounded by 
many doubts. We carried out prostate biopsy (not too of-
ten) and had to rely on its results. We also recorded the 
PSA levels; however only afterwards, since it was first 
measured every other week – later weekly.
 
After collecting the cases where we measured PSA, I 
presented a poster on the topic at the EAU conference in 
London in 1988; following this conference I presented 
the same poster at the Hungarian Urological Congress – 
however, few were interested. 
Also in the same year we were given reagents for carrying 
out 100 examinations, therefore we started to use them 
at our department.
We did not really know which groups of patients we had 
to involve and we had troubles with assessing the results 
as well. Moreover, we lacked patients, so we needed to 
get serums from other hospitals. My boss was not really 
certain about PSA either…
For all this, we managed to publish the first Hungarian 
study on PSA examinations at our department in Orvo-
si Hetilap (1) (Medical Weekly). Following this event 
we succeeded in organizing an international conference 
in Budapest in 1991. Thanks to our efforts, the use of 
PSA examinations started to spread. Hence, in 2010 the-
re were about 7000 PSA examinations at Semmelweis 
University, most of which were indicated by urologists. 
Since then assessing PSA has become a daily clinical 
practice.
Indications
In what cases should PSA be determined?
•  For medical check-ups, at male patients without symp-
toms (not financed by the Hungarian insurance).
•  In the case of positive RDE.
•  In the case of negative RDE, but the patient has frequ-
ency.
•  If the patient has already been treated with α-receptor 
inhibitors due to the complaints of benign prostatic 
hyperplasia, but there are still symptoms.
•  If PSA level – checked after a three month interval – is 
increasing.
•  Bone pains, in the case of tumor suspected X-ray or 
isotope scan.
•  In case of a patient with prostate cancer to follow up 
the effectiveness of the treatment.
•  After radical prostatectomy, PSA levels could provide 
information on biochemical failure, recurrence of di-
sease.
The PSA has been the most useful tumour marker in the medical diagnosis so far. No other markers or screening 
methods reach the specificity and sensitivity of PSA. On the other hand the PSA has also false positive and negative 
results as well.
The advantages and disadvantages of the PSA determination are discussed in our paper. The proper counselling with 
the papers and right evaluation of results should be diminished the disappointments in PSA. 
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•  The list of indications seems to be long, but whether 
patients always benefit from this examination?
•  During general medical check-ups the rate of diagno-
sing prostate tumours is very low, therefore it is not 
economical. However, those recognized at an early 
stage will definitely recover.
Moreover, the effectiveness of PSA is better than colo-
noscopy and its sensibility is high above other tumour 
markers. There was, however, an editorial article pu-
blished in the European Urology where it was noted that 
„The PSA era and its challenges are not over.” (2)
Throughout rectal examination the local tumours can 
be detected in 30%. Therefore, RDE is not capable of 
detecting all the tumours at an early stage without PSA 
examination. We cannot, however, apart from the prac-
tice!
PSA level, what should we do with it?
What level is positive in fact?
Higher levels (> 3 or > 4 ng/ml) than the level authorized 
by the laboratory?
This is not true in this way. Regardless of the higher PSA 
levels (4-10 ng/ml) we measured at our patients, tumours 
were detected only in 20-40% by biopsy. Biopsy is said 
to be unnecessary in 60-80%. Unnecessary? The number 
of tumorous patients with normal PSA levels could rea-
ch up to 15% (3). This means that prostate tumour could 
occur at those patients who have normal PSA levels (> 
2.5 ng/ml) (4). In case of bone metastasis of prostate can-
cer which causes pain to the patients, we can definitely 
be sure of finding an increased level of PSA. However, 
if we detect a suspicious shadow on the X-ray image be-
sides normal PSA levels, prostate cancer or at least me-
tastasis could likely be excluded. Furthermore, in case 
of proved malignant disease the follow-up of PSA level 
is inevitable. However, we can face surprising events in 
case of hormone resistance: tumorous progression may 
as well occur besides normal PSA levels, furthermore, 
increasing PSA levels during hormone treatment should 
indicate change in drug treatment. It is also important 
to know that cycling, horse riding, ejaculation or even 
rectal examination before blood test will increase PSA 
levels. Finasterid (drug) administered due to prostate 
hypertrophy will decrease PSA levels by 50%.
Annoying factors
PSA level arises in accordance with patient age. At the 
age of 45, the normal figure is 2.5 ng/ml, whereas at the 
age of 80 it might be 6.5 ng/ml. This is, however, not 
always true. 30% of the patients between the age of 70-
80 have the PSA level under 3 ng/ml (Table 1).
Moreover, PSA level arises in accordance with the pro-
state volume. It could be true since an enlarged prostate 
might indicate an increased PSA level. The calculation 
of PSA density (PSA level divided by prostate volume) 
might help us to avoid mistakes. The problem is that cal-
culating proper prostate volume seems to be difficult. In 
addition, PSA level increases in case of prostate inflam-
mation. This higher level of PSA could be detected three 
months later as well in 30% of the cases. The pathologi-
cal level can be normalized only after 6 months if trea-
ted properly. Therefore, in case of a patient with chronic 
prostatitis, several biopsies might be performed because 
of increased PSA level if the prostatitis is symptom-free 
and the urologist does not think of chronic inflammation. 
Nevertheless, the biopsy results do not always describe 
inflammation, since the pathologist usually searches for 
tumorous disease as indicated by the examining urolo-
gist. Therefore, in the case of suspected prostatitis cau-
sing higher PSA levels, biopsy should be preceded by an 
antibiotic treatment. As a consequence, the number of 
unnecessary biopsies could be reduced. We could sus-
pect chronic prostate inflammation in the case of pyu-
ria after a massage; however, the lack of pyuria would 
not definitely exclude prostatitis. The diurinal change of 
PSA might reach 10-20%. I wonder whether I have ma-











Oesterling 2.5 3.5 4.5 6.5
Anderson 1.5 2.5 4.5 7.5
Reed 2.5 3.5 3.5 3.5
TABLE 1. 
PSA in accordance with age based on the studies of certain authors
TABLICA 1 
Vrijednosti PSA u odnosu na starosnu dob, temeljene na istraživanjima pojedinih autora
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Other matters
Biopsy
What should we do with the patient whose PSA levels 
are steadily increasing but the biopsies are all negative? 
The reason could either be traced in the patient or in the 
method of biopsy. One reason can be the inflammation 
explained before, for instance in the case of prostate sto-
nes (which normally should not be treated) a perifocal 
inflammation occurs. The method of performing biopsy 
might provide us reasons. It is no use mentioning tho-
se cases where the biopsy samples cannot be analyzed 
and assessed. In these cases the urologist is informed 
of the insufficient sample, and the pathologist does not 
give any opinion. There are few biopsies performed 
without ultrasound guidance, however, biopsies taken 
in this way are rather leading to inadequate results. On 
contrary, ultrasound guided biopsy might provide us in-
sufficient samples. For example, the pathologist is not 
aware of which part of the prostate the samples are taken 
from, therefore, in the case of two samples taken very 
close from each other the pathology result might be mi-
sleading since cancer could be hidden in the untouched 
part of the prostate. In addition, the sample can be too 
short, too crumpled, or the pathologist can also make 
mistakes, even when he is a beginner, or he works at an 
institution where there are few urological samples. If vo-
iding symptoms are not better regardless of α-inhibitors, 
we do have to think of tumours. Also we can think of 
the fact that the patient does not take the drug regular-
ly or of a progressed stage where the administered drug 
does not have a proper effect and therefore the patient’s 
status gets no better. The annual increase in PSA level 
is 0.17 ng/ml, thus in the case of a higher annual level 
biopsy is definitely indicated, though the data are very 
variable (5).
Radical surgery
The radical prostatectomy is a curative treatment. We 
remove the prostate, the seminal vesicle and often the 
regional lymph nodes as well. (This latter treatment is 
not necessary under 10 ng/ml, but we usually perform 
this surgery) we try to cut through the urethra under the 
apex, and then we remove it from the bladder neck in 
order not to leave any prostate tissue there. The proof of 
our success is the PSA level of 0.0 ng/ml 8 weeks after 
the surgery. However, in the 30% of the cases PSA level 
can be detected 10 years after the surgery (biochemical 
failure). If there is prostate tissue remained, PSA level 
can be detected 8 weeks after the surgery, however, this 
is rather rare. Biochemical failure occurs more often in 
those patients who had higher PSA levels before the sur-
gery or when the tumour infiltrated the capsule (stage 
higher than pT2) and the Gleason score is high (more 
than 8). But why will some patients have detectable PSA 
levels 3-5 years after the surgery? I truly do not know… 
Nor does anybody…
Blessing or curse?
PSA is a blessing for those whose cancer was detected 
in an early stage.
PSA is a curse for those whose prostate cancer is reco-
gnized in an early stage, but during the histology exa-
mination the tumour was not significant (< 0.2 cm3); the 
patient might have lived without any symptoms for long 
– but he had to undergo a surgery with all its side effects 
and complications.
PSA is a curse for those whose PSA level is higher (more 
than 4 ng/ml) and his prostate is enlarged (for example 
80 g) which might explain higher PSA level; however 
since the doctor as well as the patient are in doubts, bi-
opsy will surely be performed.
PSA is a blessing for the patient who had been checked 
for 6-8 years, many biopsies were performed and finally 
he was cured with brachytherapy at the age of 72.
PSA is a curse for the patient who underwent a surgery 
even though his tumour was local and became inconti-
nent. The correction surgery, however, was successful.
PSA is a blessing for that 52-year-old father with three 
children, who after undergoing the surgery became tu-
mour-free, moreover taking sildenafil, he became potent 
as well. (His PSA is 0.0 ng/ml).
PSA is a curse for all those patients where biopsy was 
performed just because of an increased PSA level. He is 
waiting for admission to the hospital, waiting for the hi-
stology results – meanwhile he is being nervous, having 
“PSA-it is”. If the PSA is positive, he becomes more 
nervous, if negative he still remains anxious about the 
future (6).
PSA is a blessing for the man who has a zero level PSA, 
symptom-free and even more he remains potent. This is 
the so-called “trifecta”, which we are struggling to ac-
hieve. How could we apart from these paradoxes? We 
cannot put PSA aside since there is no better solution 
regardless of all the critical remarks. In the USA, 80-100 
of the male patients want to know the level of PSA, whe-
reas this number is only 30-50% in Europe (3).
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What can we do?
We have to consider PSA level very important. Exami-
ne the patient carefully (rectally, transrectal US or by 
MR examination). Control the PSA levels in order to get 
closer to the real PSA level. If we have doubts about 
the results, we do have to repeat the test. In the case of 
suspected prostatitis, administrate antibiotics and an-
tiphlogistics promptly, and check PSA afterwards. The 
treatment is the same if the inflammation is proved. We 
should measure the residual urine after voiding, if the 
volume is higher, we can allow for an increased PSA 
level. The blood should be taken before rectal examina-
tion. We can dream of a new marker – which exists alre-
ady PC3, by which we can make diagnosis after massage 
(it costs 100 or 200 Euros).
I wish everybody more blessing than curse!
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Stručni članak
SAŽETAK
PSA je poznat kao najkorisniji tumorski biljeg do sada u medicinskoj dijagnozi. Niti jedan drugi marker ili metoda 
probira ne postižu takvu specifičnost i osjetljivost. S druge strane, PSA također daje kako lažno pozitivne tako i lažno 
negativne rezultate.
U članku se raspravlja o prednostima i nedostatcima u određivanju PSA. Pravilno praćenje nalaza te korektna eva-
luacija rezultata trebale bi umanjiti moguća razočarenja koja donosi PSA. 
